Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer
The Efficacy and Safety of Sacituzumab Govitecan Plus Tislelizumab in Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Patients Who Progressed on Prior Immune Checkpoint Inhibitors (ICIs)
Shanghai Chest Hospital
28 participants
Jul 30, 2026
INTERVENTIONAL
Conditions
Summary
This is a prospective, single-center, single-arm Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with tislelizumab in patients with advanced esophageal squamous cell carcinoma whose disease has progressed following first-line immunotherapy.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Sacituzumab Tirumotecan 4mg/kg, iv, d1, Q2W ,until disease progression or intolerable toxicity. Tislelizumab，200 mg, iv, d1, Q2W, until disease progression or intolerable toxicity.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07811752